| Literature DB >> 28991460 |
Hongguang Li1, Chen Xie1, Rongfeng Lan1,2, Shuai Zha1, Chi-Fai Chan1, Wing-Yan Wong3, Ka-Lok Ho1, Brandon Dow Chan3, Yuxia Luo1, Jing-Xiang Zhang1,4, Ga-Lai Law3, William C S Tai3, Jean-Claude G Bünzli1,5, Ka-Leung Wong1.
Abstract
A unique, dual-function, photoactivatable anticancer prodrug, RuEuL, has been tailored that features a ruthenium(II) complex linked to a cyclen-europium chelate via a π-conjugated bridge. Under irradiation at 488 nm, the dark-inactive prodrug undergoes photodissociation, releasing the DNA-damaging ruthenium species. Under evaluation-window irradiation (λirr = one-photon 350 nm or two-photon 700 nm), the drug delivery process can be quantitatively monitored in real-time because of the long-lived red europium emission. Linear relationships between released drug concentration and ESI-MS or luminescence responses are established. Finally, the efficiency of the new prodrug is demonstrated both in vitro RuEuL anticancer prodrug over some existing ones and open the way for decisive improvements in multipurpose prodrugs.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28991460 DOI： 10.1021/acs.jmedchem.7b01162
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446